Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 801–900 of 1,000
Chronic Diarrhea Evaluation in the Elderly: IBS or Something Else?
Schiller, L. R. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0714-5 · Cited by 19
Katzman, M., Kim, J., Lesher, M. D., Hale, C. M., McSherry, G., Loser, M. F., Ward, M. A., & Glasser, F. D. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz352 · Cited by 15
Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients
Schluger, A., Rosenblatt, R. E., Knotts, R. M., Verna, E. C., & Pereira, M. R. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13184 · Cited by 15
Cheng, Y., & Fischer, M. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701233 · Cited by 16
Guevara, E. Y., Aitken, S. L., Olvera, A., Carlin, L. G., Fernandes, K. E., Bhatti, M. M., Garey, K. W., Adachi, J. A., & Okhuysen, P. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1184 · Cited by 15
Self-citationDoan, T. H. D., Yen‐Nicolaÿ, S., Bernet‐Camard, M., Martin‐Verstraete, I., & Péchiné, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241903 · Cited by 15
Chitapanarux, T., Wiracha, U., Winichakoon, P., Salee, P., & Traisathit, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-04986-2 · Cited by 16
“Stool testing for C. difficile toxin was conducted for patients who exhibited new or worsening symptoms following therapy 4 .”
Mikulska, M., Robin, C., Neofytos, D., Oltolini, C., Piekarska, A., Reigadas, E., Gil, L., Chemaly, R. F., Groll, A. H., Muñóz, P., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103371 · Cited by 17
Kang, M., Abeles, S. R., El-Kareh, R. E., Taplitz, R., Nyheim, E. E., Reed, S. L., Jenkins, I., Seymann, G., Myers, F. E., & Torriani, F. J. (2020) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/j.jcjq.2020.05.004 · Cited by 14
Impact of Clostridioides difficile infection on patient-reported quality of life
Han, Z., Lapin, B. R., Garey, K. W., Donskey, C. J., & Deshpande, A. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.413 · Cited by 14
Self-citationRegulation of para-cresol production in Clostridioides difficile
Harrison, M. A., Strahl, H., & Dawson, L. F. (2021) · Current Opinion in Microbiology · doi:10.1016/j.mib.2021.11.005 · Cited by 13
Clostridioides difficile colonization among very young children in resource-limited settings
Brennhofer, S. A., McQuade, E. T. R., Liu, J., Guerrant, R. L., Platts-Mills, J. A., & Warren, C. A. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.01.022 · Cited by 14
“difficile is not recommended for patients younger than two years of age [2].”
BackgroundSandora, T. J., Williams, D. N., Daugherty, K., Geer, C., Cuddemi, C., Kociolek, L. K., Chen, X., Xu, H. J., Savage, T. J., Banz, A., et al. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac059 · Cited by 14
Self-citationCalderaro, A., Buttrini, M., Farina, B., Montecchini, S., Martinelli, M., Arcangeletti, C., Chezzi, C., & Conto, F. D. (2022) · Microorganisms · doi:10.3390/microorganisms10071477 · Cited by 14
Clostridioides difficile Infection in Patients after Organ Transplantation—A Narrative Overview
Dudzicz, S., Więcek, A., & Adamczak, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154365 · Cited by 15
Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements
Mattana, M., Tomasello, R., Cammarata, C., Carlo, P. D., Fasciana, T., Giordano, G., Lucchesi, A., Siragusa, S. M., & Napolitano, M. (2022) · Microorganisms · doi:10.3390/microorganisms10081624 · Cited by 16
“Other severe complications of CDAC include toxic megacolon, perforation, intestinal paralysis, kidney failure, and systemic inflammatory response syndrome (SIRS) [10].”
BackgroundPal, R., & Seleem, M. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267859 · Cited by 16
Diniz, A. N., Moura, L. N. F., Cruz, D. S. G., Oliveira, C. A., Figueiredo, H. C. P., Reis-Cunha, J. L., Vilela, E. G., Kuijper, E. J., Wilcox, M. H., Lobato, F. C. F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273013 · Cited by 17
Self-citationXu, Q., Zhang, S., Quan, J., Wu, Z., Gu, S., Chen, Y., Zheng, B., Lv, L., & Li, L. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12154-z · Cited by 14
Boeriu, A. M., Roman, A., Dobru, D. E., Stoian, M., Voidăzan, S. T., & Fofiu, C. (2022) · Diagnostics · doi:10.3390/diagnostics12123196 · Cited by 15
Vuillamy, C., Arnault, J., Fuméry, M., Mortier, L., Monestier, S., Mansard, S., Bens, G., Duval-Modeste, A.-B., Funck‐Brentano, E., Jeudy, G., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000878 · Cited by 13
Zhou, Y., Bi, Z., Hamilton, M. J., Zhang, L., Su, R., Sadowsky, M. J., Roy, S., Khoruts, A., & Chen, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914621 · Cited by 16
Reviewing the Clostridioides difficile Mouse Model: Insights into Infection Mechanisms
Fachi, J. L., Vinolo, M. A. R., & Colonna, M. (2024) · Microorganisms · doi:10.3390/microorganisms12020273 · Cited by 18
“The current strategy for managing and treating patients with CDI typically involves a multifaceted approach [46].”
BackgroundKim, J., Myung, R., Kim, B., Kim, J., Kim, T., Lee, M. S., Kim, U. J., Park, D. W., Ys, K., Lee, C., et al. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e118 · Cited by 19
“13 The incidence of CDI was estimated based on the number of CDI cases per 10,000 patient-days or per 1,000 admissions.”
MethodRueedi, G., Panchaud, P., Friedli, A., Specklin, J., Hubschwerlen, C., Blumstein, A.-C., Caspers, P., Enderlin-Paput, M., Jacob, L., Kohl, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00558 · Cited by 16
Recurrence ofClostridium difficileinfection in the Western Australian population
Alfayyadh, M., Collins, D. A., Tempone, S., McCann, R. L., Armstrong, P., Riley, T. V., & Cook, A. G. (2019) · Epidemiology and Infection · doi:10.1017/s0950268819000499 · Cited by 16
“Clinical practice guidelines recommend a period of >14 days from initial infection to second episode to be defined as recurrent CDI [43].”
BackgroundYuille, S., Mackay, W. G., Morrison, D. J., & Tedford, C. M. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.004 · Cited by 18
Aktualisierung der S3-Leitlinie Colitis ulcerosa 2019
Kucharzik, T. F., Dignass, A. U., & Siegmund, B. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1015-7048 · Cited by 14
Luzum, M., Sebolt, J. T., & Chopra, V. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.02.004 · Cited by 14
Marra, A. R., Alzunitan, M. A., Abosi, O. J., Edmond, M. B., Street, W. N., Cromwell, J. W., & Salinas, J. L. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115104 · Cited by 16
Gill, M. G., Blacketer, C., Chitti, F., Telfer, K., Papanicolas, L. E., Dann, L. M., Tucker, E. C., Bryant, R. V., & Costello, S. P. (2020) · JGH Open · doi:10.1002/jgh3.12396 · Cited by 15
Chung, H., Park, J. S., & Shin, B.-M. (2020) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.2.171 · Cited by 14
Miller, A. C., Sewell, D. K., Segre, A. M., Pemmaraju, S. V., & Polgreen, P. M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa773 · Cited by 14
Ashraf, M. F., Tageldin, O., Nassar, Y., & Batool, A. (2021) · Gastroenterology Research · doi:10.14740/gr1436 · Cited by 16
Alrawashdeh, M., Rhee, C., Hsu, H., Wang, R., Horan, K., & Lee, G. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.32114 · Cited by 14
Cherny, K. E., Muscat, E., Balaji, A., Mukherjee, J., Ozer, E. A., Angarone, M., Hauser, A. R., Sichel, J. S., Amponsah, E., & Kociolek, L. K. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac483 · Cited by 14
Nagarakanti, S., & Orenstein, R. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s400570 · Cited by 14
Singhal, T., Shah, S., Tejam, R., & Thakkar, P. (2018) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_18_340 · Cited by 14
“January 16 to December 17 (Quarter‐wise) Table 1: Clostridium difficile prevention bundle[14]”
BackgroundMethodInfluentialStuart, R. L., Marshall, C. L., Harrington, G. A., Sasko, L., McLaws, M., & Ferguson, J. (2018) · Infection Disease & Health · doi:10.1016/j.idh.2018.10.001 · Cited by 17
A comparison of air sampling methods for Clostridium difficile endospore aerosol
Cooper, C. W., Aithinne, K. A. N., Floyd, E. L., Stevenson, B. S., & Johnson, D. L. (2019) · Aerobiologia · doi:10.1007/s10453-019-09566-2 · Cited by 14
“Environmental contamination of CDI patient care rooms and adjacent areas with C. difficile spores is a recognized contact transmission risk factor, which has been demonstrated in numerous studies conducted since the 1980s (Kim et al. 1981; McDonald et al. 2018).”
BackgroundKociolek, L. K., Kutty, P. K., Polgreen, P. M., & Beekmann, S. E. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.347 · Cited by 14
“Multiplex PCR panel plus GDH/toxin EIA followed by NAAT for discordant results 6 (4)”
The human microbiota and infection prevention
Araos, R., & D’Agata, E. M. C. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.28 · Cited by 17
Wolfe, T. J. D., Kates, A., Barko, L., Darien, B. J., & Safdar, N. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-19 · Cited by 14
“Vancomycin and fidaxomicin are recommended treatments for CDI; while rates differ depending on treatment, large cohort studies have shown that overall recurrence occurs in approximately 25% of recovered patients (2, 3).”
BackgroundAn Updated Review of Clostridium difficile Treatment in Pediatrics
Campbell, C. T., Poisson, M. O., & Hand, E. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.2.90 · Cited by 16
Kong, L. Y., Davies, K., & Wilcox, M. H. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.06.001 · Cited by 14
Self-citationOchfeld, E. N., Balmert, L. C., Patel, S. J., Muller, W. J., & Kociolek, L. K. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13149 · Cited by 15
Chiu, C., Sarwal, A., Feinstein, A., & Hennessey, K. A. (2019) · Antibiotics · doi:10.3390/antibiotics8040173 · Cited by 14
“Fulminant CDI was defined as hypotensive, shock, ileus, or megacolon [2].”
BackgroundInfluentialVaughn, V. M., Greene, M. T., Ratz, D., Fowler, K. E., Krein, S. L., Flanders, S. A., Dubberke, E. R., Saint, S. K., & Patel, P. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.313 · Cited by 17
Self-citationMurray, B., Wolfe, C. L., Marra, A., Pillar, C. M., & Shinabarger, D. L. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa134 · Cited by 23
Clostridioides Difficile Infection
Ferrari, L., & Fichera, A. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001900 · Cited by 14
Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
Chaar, A., & Feuerstadt, P. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211011953 · Cited by 14
de Stefano, M. C., Mazzanti, B., Vespasiano, F., Lombardini, L., & Cardillo, M. (2022) · Antibiotics · doi:10.3390/antibiotics11040480 · Cited by 14
“However, it is worth mentioning the clear position of the United European Gastroenterology-funded working group on this issue, as it considers the stool a transplant product and demands that competent authorities supply a comprehensive regulatory framework to ensure FMT broad access and safety [21].”
BackgroundWong, Y. K. N., Gonzalez-Orta, M. I., Saldana, C. S., Cadnum, J. L., Jencson, A. L., & Donskey, C. J. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy701 · Cited by 14
Regulating stool for microbiota transplantation
Ossorio, P. N., & Zhou, Y. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1502537 · Cited by 14
US FDA-Approved Antibiotics During the 21st Century
Hori, T., Owusu, Y., & Sun, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00144-0 · Cited by 20
Wang, L., Chen, X., Pollock, N. R., Villafuerte-Gálvez, J., Alonso, C. D., Wang, D., Daugherty, K., Xu, H. J., Yao, J., Chen, Y., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2505269 · Cited by 17
“10 The currently preferred diagnostic platforms, nucleic acid amplification of the C. difficile toxin-encoding genes, toxin immunoassay or glutamate dehydrogenase assay, cannot distinguish between colonization and disease.”
Self-citationFeuerstadt, P., Hong, S. J., & Brandt, L. J. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05804-2 · Cited by 13
“Results supporting its clinical effectiveness have been mixed, but in some refractory cases, its usage as a “chaser” following vancomycin treatment has shown some benefit, prompting its inclusion with a weak recommendation in the most recent IDSA guidelines for the treatment of CDI [3].”
BackgroundFirst isolation of Clostridioides difficile from smoked and dried freshwater fish in Cambodia
Rodriguez, C., Mith, H., Taminiau, B., Bouchafa, L., Broeck, J. V., Soumillion, K., Ngyuvula, E., García‐Fuentes, E., Korsak, N., Delmée, M., et al. (2021) · Food Control · doi:10.1016/j.foodcont.2021.107895 · Cited by 13
Milenković, B., Šuljagić, V., Perić, A. V., Dragojevic-Simic, V. M., Tarabar, O., Milanović, M., Putić, V., Tomić, D., Miljković, B., & Kovačević, S. V. (2021) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002574 · Cited by 16
Saha, S., Sehgal, K., Singh, S., Grover, M., Pardi, D. S., & Khanna, S. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001536 · Cited by 18
Lawrence, J., Kitchin, N. R. E., Anderson, A. S., Pride, M. W., Jansen, K. U., Gruber, W. C., Peng, Y., Yi, K., Knirsch, C. A., & Webber, C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.028 · Cited by 13
A review of epidemiological models of Clostridioides difficile transmission and control (2009–2021)
Lanzas, C., Jara, M., Tucker, R., & Curtis, S. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102541 · Cited by 15
Ishikawa, D., Zhang, X., Nomura, K., Seki, N., Haraikawa, M., Haga, K., Shibuya, T., Kim, Y., & Nagahara, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.779205 · Cited by 15
Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
Zhang, X., Ishikawa, D., Nomura, K., Fukuda, N., Haraikawa, M., Haga, K., Shibuya, T., Mita, T., & Nagahara, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041055 · Cited by 14
Impact of ward pharmacist-led antimicrobial stewardship in intensive care units
Hashimoto, M., Asai, S., Umezawa, K., Kohara, K., Miyazawa, M., Suzuki, Y., & Miyachi, H. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2087652 · Cited by 13
“The clinical practice guidelines of many countries have also strongly recommended AS to reduce the incidence of CD infection [17, 18].”
BackgroundAntibiotic-Associated Diarrhea Beyond C. Difficile : A Scoping Review
Selvaraj, V., & Alsamman, M. A. (2022) · Journal of Brown Hospital Medicine · doi:10.56305/001c.39745 · Cited by 19
Clostridioides difficile Infection: Landscape and Microbiome Therapeutics.
Gawey, B. J., & Khanna, S. (2023) · PubMed Central · Cited by 17
Gut–Kidney–Heart: A Novel Trilogy
Caldarelli, M., Franza, L., Rio, P., Gasbarrini, A., Gambassi, G., & Cianci, R. (2023) · Biomedicines · doi:10.3390/biomedicines11113063 · Cited by 14
Alsoubani, M., Chow, J. K. L., Rodday, A. M., Kent, D. M., & Snydman, D. R. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad622 · Cited by 17
Fernández, M. Á., Origüen, J., Rodríguez‐Góncer, I., Juan, R. S., López‐Medrano, F., Parra, P., Ruiz‐Merlo, T., Redondo, N., Orellana, M. Á., Aguado, J. M., et al. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04729-z · Cited by 14
Song, M., Zhang, S., Zhang, Z., Guo, L., Liang, W., Li, C., & Wang, Z. (2024) · mSystems · doi:10.1128/msystems.00602-24 · Cited by 14
Greening Infection Prevention and Control: Multifaceted Approaches to a Sustainable Future
Lee, P. S., Frantzis, I., & Abeles, S. R. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae371 · Cited by 19
Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease
Vaughn, B. P., Khoruts, A., & Fischer, M. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003076 · Cited by 13
Jiménez, A., Araya, R., Hidalgo, D. P., Camacho-Mora, Z., Du, T., Golding, G. R., Astorga, G. L., Rodríguez, C., & Quesada-Gómez, C. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.03.027 · Cited by 13
Barron, J. S., Lattes, A., & Marcus, E. (2018) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-018-0293-2 · Cited by 13
Schwenk, H. T., Bio, L. L., Kruger, J. F., & Banaei, N. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy117 · Cited by 13
From germ theory to germ therapy
Chen, C., Chen, Y., Liou, J., & Wu, M. (2019) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12011 · Cited by 18
“using FMT after antibiotic failure for at least two CDI recurrences (three total episodes).(51) The American College of Gastroenterology recom-”
MethodSandlund, J., & Wilcox, M. H. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01885-18 · Cited by 13
Self-citationShinkawa, H., Tanaka, S., Takemura, S., Amano, R., Kimura, K., Nishioka, T., Ito, T., Miyazaki, T., Ishihara, A., & Kubo, S. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12267 · Cited by 13
Caupenne, A., Ingrand, P., Ingrand, I., Forestier, E., Baudron, C. R., Gavazzi, G., & Paccalin, M. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.07.002 · Cited by 13
Stevens, V. W., Shoemaker, H. E., Jones, M., Jones, B. E., Nelson, R. E., Khader, K., Samore, M. H., & Rubin, M. A. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.8 · Cited by 13
Tran, N. N., Mills, J., Zimmerman, C., Gandhi, T. N., Tribble, A. C., Petty, L. A., Nagel, J. L., Brancaccio, A., Scappaticci, G. B., Patel, T. S., et al. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.236 · Cited by 13
Maestri, A. C., Raboni, S. M., Morales, H. M. P., Ferrari, L. F., Tuon, F. F., Losso, A. W., Marconi, C., & Nogueira, K. D. S. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102238 · Cited by 17
Toth, D. J. A., Keegan, L. T., Samore, M. H., Khader, K., O’Hagan, J. J., Yu, H., Quintana, A., & Swerdlow, D. L. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.081 · Cited by 15
Yu, L., Palafox-Rosas, R., Luna, B. M., & She, R. C. (2020) · Antibiotics · doi:10.3390/antibiotics9100684 · Cited by 15
Aràjol, C., Gómez, A. A., González-Suárez, B., Casals‐Pascual, C., Martí, S., Luzón, M. A. D., Soriano, À., & Guardiola, J. (2020) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.07.027 · Cited by 13
Dembrovszky, F., Gede, N., Szakács, Z., Hegyi, P. J., Kiss, S., Farkas, N., Molnár, Z., Imrei, M., Dohos, D., & Péterfi, Z. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00356-9 · Cited by 14
Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines
Khurana, S., Kahl, A., Yu, K., & Dupont, A. W. (2020) · Faculty Reviews · doi:10.12703/b/9-13 · Cited by 15
The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile
Skinner, A. M., Phillips, S. T., Merrigan, M. M., O’Leary, K. J., Sambol, S. P., Siddiqui, F., Peterson, L. R., Gerding, D. N., & Johnson, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010096 · Cited by 13
Self-citationElfassy, A., Kalina, W. V., French, R., Nguyen, H. T., Tan, C. Y., Sebastian, S., Wilcox, M. H., Davies, K., Kutzler, M. A., Jansen, K. U., et al. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102415 · Cited by 14
Self-citationAlexander, T., Snowden, J. A., Burman, J., Chang, H., Papa, N. D., Farge, D., Lindsay, J. O., Malard, F., Muraro, P. A., Nitti, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722436 · Cited by 12
Yang, J., Meng, L., & Yang, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00672-22 · Cited by 15
Khuvis, J., Alsoubani, M., Rodday, A. M., & Doron, S. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.03.009 · Cited by 13
Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
Yamaki, J., Chawla, S., Tong, S., Lozada, K. A., & Yang, S. (2022) · Antibiotics · doi:10.3390/antibiotics11050537 · Cited by 14
“These factors include exposure to antibiotic therapy or proton pump inhibitors, age 65 and over, ulcerative colitis, immunosuppression, and receipt of chemotherapy [5,6].”
BackgroundNeue Leitlinien und Daten zu Clostridium difficile – Was ändert sich?
Lübbert, C., Lippmann, N., & von Braun, A. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0585-9595 · Cited by 13
Prohaska, L., Mahmoudjafari, Z., Shune, L. O., Singh, A. K., Lin, T. L., Abhyankar, S., Ganguly, S., Grauer, D. W., McGuirk, J. P., & Clough, L. A. (2018) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2018.05.001 · Cited by 13
Multidisciplinary Approach to Clostridium difficile Infection in Adult Surgical Patients
Turner, M. C., Behrens, S., Webster, W. L., Huslage, K., Smith, B. A., Wrenn, R., Woody, R., & Mantyh, C. R. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.12.045 · Cited by 13
Red Man Syndrome with Oral Vancomycin: A Case Report
Arroyo-Mercado, F. M. M., Khudyakov, A., Chawla, G. S., Cantres-Fonseca, O. J., & McFarlane, I. M. (2019) · American Journal of Medical Case Reports · doi:10.12691/ajmcr-7-1-5 · Cited by 13
Sandlund, J., Mills, R., Griego-Fullbright, C., Wagner, A., Estis, J., Bartolome, A., Almazan, A., Tam, S., Biscocho, S., Abusali, S., et al. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.04.002 · Cited by 13
Clostridium difficile Infection in Children
Alvarez, A. M., & Rathore, M. H. (2019) · Advances in Pediatrics · doi:10.1016/j.yapd.2019.03.010 · Cited by 13
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.